



IMAGION BIOSYSTEMS LIMITED

(ASX: IBX)

28 January 2020

Imagion Biosystems appoints new Vice President Clinical & Regulatory Affairs

MELBOURNE — Imagion Biosystems Limited (ASX: IBX), a company dedicated to improving healthcare through the earlier detection of cancer, announces the appointment of Dr. Oliver Steinbach as Vice President of Clinical and Regulatory Affairs. Dr. Steinbach will serve as the lead executive in the development and execution of Imagion Biosystems' overall clinical and regulatory strategy, focusing in the near-term on initiating a first-in-human study for HER2 metastatic breast cancer this year.

Dr. Steinbach has more than 20 years of pharmaceutical, diagnostics and medical device industry experience, bringing multiple diagnostic and image-guided therapy products through the clinic into the market. Dr. Steinbach spent eight years at ALTANA Pharma, an international, innovative pharmaceutical company and 12 years at Philips, a global leader in diagnostic and image-guided solutions, where he was part of the Clinical Research group that managed clinical studies and regulatory submissions related to diagnostic, therapeutic and pharmaceutical products including molecular imaging contrast agents.

"We are very excited to have Oliver join Imagion," said Bob Proulx, Executive Chairman. "His experience in managing clinical collaborations for medical imaging products is ideal for our organisation. This hire comes at just the right time as we are moving into the first phase of clinical work."

After having raised \$3.3M in a Rights Offering in November 2019, the Company is now using the funds to complete the initial steps of its upcoming first-in-human study for HER2 metastatic breast cancer. This includes manufacturing of its proprietary nanoparticles and gaining regulatory and clinical site authorisation for the study.

-ENDS

About Imagion Biosystems

Imagion Biosystems is developing a new non-radioactive and safe diagnostic imaging technology. Combining biotechnology and nanotechnology the Company aims to detect cancer and other diseases earlier and with higher specificity than is currently possible. Imagion Biosystems listed on the Australian Securities Exchange (ASX) in June 2017.

This Announcement has been approved by the Disclosure Committee of Imagion Biosystems Limited

For further information please visit www.imagionbiosystems.com

U.S. Media Contact:

Matthew Wygant
matthew@biotechwriting.com
+1-408-905-7630

Australian Media & Investor Relations:

Kyahn Williamson, WE Communications
We-AUImagionBiosystems@we-worldwide.com
+61-3-9866-4722

Imagion Biosystems Limited

ACN 616 305 027

Level 8, 555 Bourke Street, Melbourne VIC 3000
www.imagionbiosystems.com

For personal use only